 Shares of Oxford Immunotec Global NASDAQ:OXFD remained unaffected at 11.76 after the company reported Q1 results.Quarterly Results Earnings per share were down 233.33 over the past year to 0.20, which missed the estimate of 0.15.Revenue of 13,911,000 less by 5.94 from the same period last year, which beat the estimate of 13,450,000.Outlook Earnings guidance hasnt been issued by the company for now.Q2 revenue expected between 5,000,000 and 6,000,000.How To Listen To The Conference Call Date: May 05, 2020View more earnings on OXFDTime: 10:01 PM ETWebcast URL: Action 52-week high: 17.7752-week low: 8.37Price action over last quarter: down 10.98Company Overview Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The companys research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.See more from Benzinga JELD-WEN Holding: Q1 Earnings Insights Recap: Crestwood Equity Partners Q1 Earnings Atkore International: Q2 Earnings InsightsC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 